抗体

抗血管内皮生长因子受体1 FLT1兔单克隆抗体

M00534

100微升

315美元

单克隆

domestic rabbit

未共轭

AFH-6

人类, 小鼠

免疫印迹, 免疫组化, 免疫细胞化学, 免疫沉淀, 流式细胞仪

抗血管内皮生长因子受体1 FLT1兔单克隆抗体

315美元

100微升

单克隆

AFH-6

兔

人类, 小鼠, 大鼠

流式细胞仪, 免疫沉淀, IF, 免疫组化, 免疫细胞化学, 免疫印迹

免疫印迹1:500-1:2000。 免疫组化1:50-1:200。 免疫细胞化学/IF 1:50-1:200。 免疫沉淀1:50。 流式细胞仪1:50

Boster Bio Anti-VEGF Receptor 1 FLT1 Rabbit Monoclonal Antibody catalog # M00534. Tested in Flow Cytometry, IP, IF, IHC, ICC, WB applications. This antibody reacts with Human, Mouse, Rat.

Actual concentration vary by lot. Use suggested dilution ratio to decide dilution procedure.

FLT1

P17948

A synthesized peptide derived from human VEGF Receptor 1

液体

兔IgG在磷酸盐缓冲液, pH值7.4, 150mM氯化钠, 0.02% 叠氮化钠和50% 甘油, 0.4 0.5毫克/毫升BSA

亲和色谱

Store at -20°C for one year. For short term storage and frequent use, store at 4°C for up to one month. Avoid repeated freeze-thaw cycles.

血管内皮生长因子受体1

血管内皮生长因子受体1;VEGFR-1;2.7。 10.1;FMS样酪氨酸激酶1;FLT-1;酪氨酸蛋白激酶FRT;酪氨酸蛋白激酶受体FLT;FLT;血管通透性因子受体;FLT1;FLT, FRT, VEGFR1;

150769分子量

Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion. May play an essential role as a negative regulator of embryonic angiogenesis by inhibiting excessive proliferation of endothelial cells. Can promote endothelial cell proliferation, survival and angiogenesis in adulthood. Its function in promoting cell proliferation seems to be cell-type specific. Promotes PGF-mediated proliferation of endothelial cells, proliferation of some types of cancer cells, but does not promote proliferation of normal fibroblasts (in vitro). Has very high affinity for VEGFA and relatively low protein kinase activity; may function as a negative regulator of VEGFA signaling by limiting the amount of free VEGFA and preventing its binding to KDR. Likewise, isoforms lacking a transmembrane domain, such as isoform 2, isoform 3 and isoform 4, may function as decoy receptors for VEGFA. Modulates KDR signaling by forming heterodimers with KDR. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, leading to activation of phosphatidylinositol kinase and the downstream signaling pathway. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Phosphorylates SRC and YES1, and may also phosphorylate CBL. Isoform 1 phosphorylates PLCG. Promotes phosphorylation of AKT1 at 'Ser-473'. Promotes phosphorylation of PTK2/FAK1. Isoform 7 has a truncated kinase domain; it increases phosphorylation of SRC at 'Tyr-418' by unknown means and promotes tumor cell invasion.

Isoform 1: Cell membrane; Single-pass type I membrane protein. Endosome. Autophosphorylation promotes ubiquitination and endocytosis.

Detected in normal lung, but also in placenta, liver, kidney, heart and brain tissues. Specifically expressed in most of the vascular endothelial cells, and also expressed in peripheral blood monocytes. Isoform 2 is strongly expressed in placenta. Isoform 3 is expressed in corneal epithelial cells (at protein level). Isoform 3 is expressed in vascular smooth muscle cells (VSMC).

Angiogenesis, Cancer, Cancer Metabolism, Cardiovascular, Growth Factors, Invasion/Microenvironment, Metabolism, Metabolism Processes, Pathways And Processes, Protein Phosphorylation, Response To Hypoxia, Signal Transduction, Tyrosine Kinases